Quake Stephen 4

What Happened
Stephen Quake, a director of AbCellera Biologics (ABCL), received a grant of 111,701 derivative shares/options on 2026-06-11. The filing lists an acquisition price of $0.00 (derivative award), meaning no cash was paid as part of this grant. This was an equity award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-12 (appears timely).
• Transaction type: Award/Grant (derivative) of 111,701 shares; reported price $0.00.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: The shares subject to the option vest and become exercisable at the 2027 Annual General Meeting, subject to Quake’s continuous service (per F1).
• Not a sale or purchase—no immediate cash proceeds; no 10% owner designation or 10b5-1 plan noted.

Context
This is a typical director equity award intended as compensation/retention. Because the award vests at the 2027 AGM and is recorded as a derivative, it does not represent an immediate buy or sell signal. Retail investors tracking insider activity usually place more weight on outright purchases than on compensation grants, though grants can be useful to monitor alignment of management/directors with shareholder interests.